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Carvedilol, a β-adrenoreceptor antagonist with strong antioxidant activity, produces a high degree of cardioprotection in a variety of
experimental models of ischemic cardiac injury. Although growing evidences suggest specific effects on mitochondrial metabolism, how
carvedilol would exert its overall activity has not been completely disclosed. In the present work we have investigated the impact of carvedilol-
treatment on mitochondrial bioenergetic functions and ROS metabolism in H9C2 cells. This analysis has revealed a dose-dependent decrease in
respiratory fluxes by NAD-dependent substrates associated with a consistent decline of mitochondrial complex I activity. These changes were
associated with an increase in mitochondrial H2O2 production, total glutathione and protein thiols content. To evaluate the antioxidant activity of
carvedilol, the effect of the exposure of control and carvedilol-pretreated H9C2 cells to H2O2 were investigated. The H2O2-mediated oxidative
insult resulted in a significant decrease of mitochondrial respiration, glutathione and protein thiol content and in an increased level of GSSG.
These changes were prevented by carvedilol-pretreatment. A similar protective effect on mitochondrial respiration could be obtained by pre-
treatment of the cells with a sub-saturating amount of rotenone, a complex I inhibitor.
We therefore suggest that carvedilol exerts its protective antioxidant action both by a direct antioxidant effect and by a preconditioning-like
mechanism, via inhibition of mitochondrial complex I.
© 2007 Elsevier B.V. All rights reserved.Keywords: Mitochondria; Respiratory chain; Complex I; Carvedilol; Oxidative stress; Glutathione1. Introduction
Cardiovascular diseases represent a leading cause of death
worldwide. Considerable evidence suggests that oxidative
stress is intimately involved in the pathogenesis of various
forms of cardiovascular diseases, including myocardial ische-
mia–reperfusion injury, congestive heart failure, arteriosclero-
sis, and drug-induced cardiomyopathy [1–4]. In support to
these notions, administration of exogenous antioxidant agents
has been shown to result in protective effects on oxidative
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doi:10.1016/j.bbabio.2007.01.023Carvedilol, a non-selective β-blocker with both β1- and
β2-adrenoreceptor and α1-receptor blocking properties, is
widely used as anti-hypertensive medicament [7] and
improves cardiac function in patients with heart failure by
decreasing heart rate, myocardial contractility and myocardial
oxygen demand [8–10]. Some of the carvedilol effects have
been assigned to its antioxidant action [6,11,12] which might
contribute to the higher cardioprotection afforded by carve-
dilol as compared with other β-blockers [13,14]. Carvedilol
has been shown (i) to prevent hydroxyl radicals-induced
decrease in sarcoplasmatic reticulum Ca2+-ATPase activity [15],
(ii) to attenuate the hydrogen peroxide (H2O2)-mediated de-
crease of mRNA for Ca2+-ATPase by enhancing gene tran-
scription for this enzyme [16], (iii) to exert protection against
oxidative damages induced by ischemia–reperfusion [17] and
by the ROS-producing hypoxanthine/xanthine oxidase activated
system [18,19].
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overall activity has not been completely disclosed and several
hypotheses have been proposed.
An interesting aspect of the carvedilol action is related to its
specific effect on mitochondrial metabolism. Although the primary
role of mitochondria is the ATP generation through oxidative
phosphorylation (OXPHOS), these organelles are also involved in
the initiation and execution of apoptotic cell death and in the
calcium and iron homeostasis [20]. Furthermore, the electron
transfer along the mitochondrial electron transport complexes can
be associated with single electron reduction of molecular oxygen
to form superoxide anions. It has been estimated that as much as
1–2% of the overall oxygen consumption can result in the
formation of reactive oxygen species (ROS), with the majority
being generated by mitochondria [21].
Evidence has emerged that energy deficiency can have a
causative link with heart failure, but, as well, it may be
adaptively regulated under certain conditions. For example, in
the ischemic heart, a reduction in the mitochondrial oxidative
capacity serves to reduce oxygen consumption in response to
the limited O2 availability. Therefore, drugs able to modulate
mitochondrial functions might have new and unexpected
development in the clinical practice and, in particular, in
patients with cardiac disease.
Carvedilol has been shown to prevent, in isolated heart
mitochondria, the calcium-induced mitochondrial permeability
transition (MPT) occurring in the post-ischemic reperfusion of
the heart [22] by avoiding protein thiol oxidation [23]. It also
improves mitochondrial energy production, thus decreasing the
oxidative phosphorylation lag phase during ischemia [10]. On
the other hand, carvedilol can exert pro-oxidant effects. In fact,
it has been reported that this drug can induce, in isolated
mitochondria, a marked inhibition of mitochondrial respiration
by NAD-dependent substrates [24] and a specific inhibition of
mitochondrial complex I activity [24,25], with these effects
being associated with an increased production of ROS.
In the first part of the present work we have investigated the
effects of carvedilol on mitochondrial respiratory fluxes, OXPHOS
enzymatic activities and oxidative stress markers in H9C2 cells.
The most important observation obtained by this analysis is the
dose-dependent decrease of respiratory fluxes by NAD-dependent
substrates and the parallel decline of complex I activity. These
effects were associated with an increase in mitochondrial H2O2
production and in total glutathione and protein thiols content. We
have then studied the antioxidant properties of the drug by applying
a pro-oxidant insult (H2O2) on carvedilol pre-treated cells. The
results show that carvedilol pre-treatment induces a significant
protection from subsequent oxidative damage and suggest the
possibility of a preconditioning-like mechanism of action besides a
direct antioxidant effect of the drug.
2. Materials and methods
2.1. Cell lines and media
The H9C2 cell line, derived from embryonic rat heart [26], was purchased
from American Type Culture Collection (ATCC; Virginia, USA). Cells were
cultured, without tubular structure formation, in high-glucose Dulbecco'smodified Eagle's medium (DMEM) supplemented with 10% (v/v) foetal bovine
serum (FBS), 1% (v/v) L-glutamine, 1% (v/v) penicillin/streptomycin, at 37 °C
in a humidified atmosphere of 10% CO2. Cells were plated and subcultured at
70–80% of confluence according to ATCC Product information sheet. Cell
viability was assessed by trypan blue exclusion test.
2.2. Carvedilol treatment
Carvedilol, kindly supplied by GlaxoSmithKline (West Sussex, UK), was
dissolved in dimethyl sulfoxide (DMSO) and added to the cells at 60–70% of
confluence, at the indicated final concentrations. Cells treated in parallel with
equal amounts of DMSO were used as control cells. However, the maximal
DMSO concentration reached in our experiments (about 0.05%) did not cause
any detectable effect on cell viability and/or on any other parameter measured in
the present work. No change in respiration rate was observed in time 0 control as
well as upon direct addition of carvedilol into the oxygraphic chamber both to
control intact cells and to control permeabilized cells respiring on complex I or
complex II substrates. A time response curve of cellular respiration at 10 μM
carvedilol indicated that the maximal inhibitory effect of respiratory activity was
reached at 12 h and remained fairly constant up to 24–28 h of treatment (data not
shown). We therefore decided to set the standard incubation time with carvedilol
at 24 h. Under these conditions, no effect on cell viability could be detected. In
order to investigate the protective effect of carvedilol from oxidative insults,
control cells or carvedilol (10 μM)-pretreated cells, were exposed, for additional
2 h, to increasing concentration of H2O2, upon removal of DMSO- or carvedilol-
containing medium, respectively. The same conditions were used to investigate
the effects of rotenone (0.1 nM)-pretreatment on H2O2 (200 μM)-mediated
oxidative insult.
2.3. Measurement of endogenous respiration rates in intact cells and
substrate-supported respiration rates in digitonin-permeabilized cells
The respiratory activity was measured polarographically with a Clark-type
oxygen electrode in a water-jacketed chamber, (Hansatech Instruments, Norfolk,
UK), magnetically stirred at 37 °C essentially as previously described [27].
Cells, fluid changed 1 day before the measurement, were collected by
trypsinization and centrifugation and resuspended at 1–3×106 cells/ml in TD
Buffer (0.137 M NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 25 mM Tris–HCl, pH
7.4), for measurements of mitochondrial respiratory fluxes, or in Buffer A
(75 mM sucrose, 5 mM KH2PO4, 40 mM KCl, 0.5 mM EDTA, 3 mM MgCl2,
30 mM Tris–HCl, pH 7.4), supplied with 0.3 mM P1,P5-di(adenosine-5′)
pentaphosphate (Ap5A) to prevent dissipation of ADP by adenylate kinase, for
the measurements of OXPHOS efficiency (P/O ratios). The cell suspension was
transferred to the polarographic chamber and an aliquot was utilized for cell
counting and protein determination. After permeabilization by digitonin, where
indicated, substrates and inhibitors of mitochondrial OXPHOSwere added at the
following concentrations: pyruvate (5 mM)/malate (2.5 mM), succinate (5 mM),
ascorbate (10 mM)+TMPD (0.4 mM), rotenone (200 nM), antimycin A (15 nM)
and cyanide (1 mM). In the experiments for OXPHOS efficiency measurement,
the substrates pyruvate/malate and succinate were followed by addition of
0.17 mM ADP and 0.08 mM ADP, respectively, to induce transient stimulation
of oxygen consumption.
2.4. Determination of mitochondrial enzyme activities
Cells, collected by trypsinization and centrifugation, were resuspended in
buffer A, as described above, counted and supplemented with 30 μg/106 cells of
digitonin. After 1–2 min, the cell suspension was further diluted by adding 9
volumes of the same buffer and centrifuged; the pellet was then resuspended in
hypotonic medium (25 mM potassium phosphate, pH 7.2, 5 mM MgCl2),
supplemented with antiproteases cocktail tablet (Boehringer Mannheim). In
order to allow complete accessibility of substrates to the inner mitochondrial
membrane enzymes, samples were freeze–thawed three times, gently shaken
and then resuspended in the assay buffer described above. All enzyme activities
were measured spectrophotometrically with a Beckman DU7400 equipped with
a rapid-mixing apparatus at 30 °C essentially as previously described [28] with
some minor modifications.
Fig. 1. Measurements of respiration rates in H9C2 cells. (A) Typical
polarographic recording of basal and DNP-uncoupled respiration rates by
endogenous substrates in intact cells and of exogenous substrate-dependent
respiration rates in digitonin-permeabilized cells. (B) Typical polarographic
recording of ADP-stimulated respiration rates by exogenous substrates. Cells,
H9C2 cells; DNP, dinitrophenol (40 μM); Dig., digitonin (30 μg/106 cells); P/M,
pyruvate (5 mM)/malate (2.5 mM); ADP (0.17 and 0.08 mM for P/M and Succ,
respectively); Rot, rotenone (200 nM); Succ, succinate (5 mM); Ant.A,
antimycin A (15 nM); Asc/TMPD, ascorbate (10 mM)+TMPD (0.4 mM); KCN,
potassium-cyanide (1 mM).
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buffer described above supplemented with fatty-acid free bovine serum
albumin (BSA) (2.5 mg/ml) in the presence of 2 mM KCN, antimycin A
(3 μg/ml) and 65 μM decylubiquinone, using 250 μg/ml of protein, by
following the rotenone-sensitive initial rate of NADH oxidation at 340–425 nm
(Δε=6.81 mM−1·cm−1). Rotenone (2 μg/ml) inhibited the enzymatic activity by
75–80%.
Succinate-cytochrome c oxidoreductase (complex II+ III) activity was
measured at 550–540 nm (Δε=19.1 mM−1·cm−1) as initial rate of antimycin-
sensitive cytochrome c reduction. Prior to the measurement, proteins (130 μg/
ml) were incubated for 10 min in the assay buffer in the presence of 20 mM
succinate. Rotenone (3 μg/ml), 2 mM KCN and 65 μM decylubiquinone were
added to the assay buffer and after baseline recording, the reaction was started by
the addition of 20 μM ferricytochrome c. The activity was 90–95% inhibited by
antimycin A (2 μg/ml).
Cytochrome c oxidase (complex IV) activity was measured by following the
oxidation of ferrocytochrome c at 550–540 nm (Δε=19.1 mM−1·cm−1).
Enzymatic activity was estimated in the assay buffer supplemented with 500 μM
dodecyl maltoside in the presence of antimycin A (3 μg/ml), using 80 μg/ml of
protein, as the apparent first-order rate constant after all cytochrome c oxidation
induced by the addition of few grains of potassium hexacyanoferrate. This rate
was inhibited over 95% by KCN (2 mM).
Citrate synthase activity was used as mitochondrial matrix enzymatic
marker. Mitochondrial proteins (80 μg/ml), 0.25 mM acetyl-coenzyme A, and
0.2 mM DTNB were added to a Tris–HCl buffer (10 mM), pH 7.4, containing
0.2% (v/v) Triton X-100. The reaction was started by the addition of 0.4 mM
oxalacetate and the initial rate was measured following the reduction of DTNB
at 412–360 nm (Δε=13.6 mM−1·cm−1).
Protein concentration was determined according to Bradford method, using
BSA as standard.
2.5. Free radical production assay
ROS production was measured using the cell permeant probe 2′–7′
dichlorodihydrofluorescin diacetate (DCFDA) which passively diffuses into
cells where intracellular esterases cleave the acetate groups to form the
impermeable DCFH2 which remains trapped within the cell [29]. After 24-h
incubation with carvedilol, cells were collected by trypsinization and
resuspended in a small volume of phosphate-buffered saline (PBS) medium.
3×105 cells were then incubated in 800 μl of Buffer A with 5 μM DCFDA for
10 min in the dark at 37 °C and the linear fluorescence increase (507 nm
excitation and 530 nm emission wavelength) caused by the ROS-dependent
oxidation of DCFH2 to the fluorescent compound dichlorofluorescein (DCF)
was measured with a Jasco FP6200 spectrofluorimeter.
2.6. Measurement of total (GSH) and oxidized (GSSG) glutathione
and of protein sulfhydryl groups (PSH)
Cells, collected by trypsinization and centrifugation, were resuspended in
hypotonic medium (25 mM potassium phosphate, pH 7.2, 5 mM MgCl2),
supplemented with antiproteases cocktail tablet (Boehringer Mannheim) at a
protein concentration of 1.5–2.0 mg protein/ml and homogenized with a
glass/glass potter. For total glutathione (GSH) and oxidized fraction of
glutathione (GSSG) measurement, proteins were precipitated with 25%
sulfosalicylic acid (SSA) (w/v) and separated by centrifugation at 12,000×g
for 3 min. The supernatant was analyzed for GSH by using the GSSG
reductase 5,5-dithiobis-nitrobenzoic acid (DTNB) recycling procedure [30].
For the determination of GSSG, the SSA supernatant was incubated for 1 h
after careful addition of 2-vinylpyridine and triethanolamine. Absorbance was
measured at 412 nm by using the GSSG reductase recycling procedure [30].
For protein sulfhydryl groups (PSH) measurement, proteins were precipitated
with 4% SSA (w/v) and centrifuged at 10,000×g for 5 min. The resulting
pellet was washed twice with 2% SSA and resuspended in 800 μl of 6 M
guanidine. Absorbance was measured at 412 and 530 nm before and 30 min
after incubation with 50 μl of 10 mM DTNB [30]. Protein concentration in
guanidine dissolved samples was measured by using a Bio-Rad kit for the
assay of proteins.2.7. Statistical analysis
Data are expressed as means±standard deviation (SD) and were statistically
analyzed by the Student's t test.3. Results
3.1. Effect of carvedilol on mitochondrial respiratory
capacities
To investigate the effects of carvedilol on mitochondrial
functions in H9C2 cardiomyocytes, we have optimized a
method [27] for the analysis of respiratory fluxes and OXPHOS
efficiency in intact and digitonin-permeabilized cells. In Fig. 1A
it is reported a typical polarographic tracing of a standard
experiment for the measurement of respiratory capacities.
About 2×106 cells/ml were suspended in TD Buffer and,
after recording the endogenous respiration rate, the maximal
endogenous respiratory capacity was measured by adding the
uncoupler dinitrophenol (DNP) at a final concentration of
40 μM. This concentration was chosen from preliminary
Fig. 3. Effect of carvedilol on maximal mitochondrial respiratory capacities in
digitonin-permeabilized cells. H9C2 cells were treated with carvedilol at the
indicated concentrations for 24 h before measurement of cell respiration.
Oxygen consumption rates, expressed as percentage of control cell values, were
measured polarographically in the presence of DNP using pyruvate/malate
(100%=3.19±0.15 nmol O2 /min/10
6 cells) (▪) or succinate (100%=2.67±
0.11 nmol O2 /min/10
6 cells) (□) as exogenous respiratory substrates in
digitonin-permeabilized cells. The data represent the means±SD from eight
independent experiments. For experimental conditions, see under Materials and
methods. *p<0.05; **p<0.01 carvedilol-treated cells versus control cells.
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stimulation of the respiratory rate (data not shown) [27].
Afterwards, digitonin was added as permeabilizing agent at a
final concentration of 30 μg/106 cells. Also in this case, a
preliminary digitonin titration was carried out in order to choose
the optimal detergent concentration corresponding to the
minimal one eliciting the highest respiration rate by the poorly
membrane-permeant succinate [27] (data not shown). Follow-
ing digitonin incubation (2 min), the maximal DNP-uncoupled
respiratory fluxes by pyruvate/malate, (complex I+ III+ IV),
succinate, (complex II+ III+ IV) and ascorbate+TMPD (com-
plex IV) were measured as rates sensitive to inhibition by
rotenone, antimycin A and cyanide, respectively.
As shown in Fig. 1B, for the measurements of OXPHOS
efficiency (P/O ratios), ∼3 ×106 cells were resuspended in the
assay buffer (Buffer A) and, after permeabilization by digitonin,
pyruvate/malate and succinate (+rotenone) were added as
respiratory substrates followed by a pulse of subsaturating
concentrations of ADP, to induce transient stimulation of the
oxygen consumption rate (state 3 respiration). Upon exhaustion
of the added ADP the state 4 respiration rate was recorded. The
P/O ratio and the respiratory control ratio (RCR) could be
therefore calculated as the ratio between the amount (nano-
moles) of added ADP and the oxygen (natoms) consumed
during the ADP-induced state 3 respiration and as the ratio
between state 3 and state 4 respiration rates, respectively.
The effects of carvedilol-treatment of heart-derivedH9C2 cells
on the basal and the DNP-uncoupled respiration rates by
endogenous substrates are shown in Fig. 2. A dose-dependent
decrease was observed for both respiratory fluxes. The most
significant difference was detected in the DNP-uncoupled endo-
genous respiration rate which was inhibited by 32% (p<0.005,
n=8) in the presence of 20 μM carvedilol. The data also reveal
a dose-dependent decrease by carvedilol in the stimulatory effect
of the uncoupler DNP on the endogenous respiration rates.
In order to understand whether the observed decrease of the
respiratory fluxes was due to the impairment of specific steps ofFig. 2. Effect of carvedilol on endogenous respiration rates in intact cells. H9C2
cells were treated with carvedilol at the indicated concentration for 24 h before
measurement of cell respiration. Oxygen consumption rates were measured
polarographically in the absence (▪) and in the presence (□) of the uncoupler
DNP. The data represent the means±SD from eight independent experiments.
For experimental details, see under Materials and methods. *p<0.01 carvedilol-
treated cells versus control cells for DNP-endogenous respiration measurement.the respiratory chain, the effect of carvedilol on the maximal
oxygen consumption rates (in the presence of DNP) by
exogenous substrates was measured in digitonin-permeabilized
cells as shown in Fig. 1A. The results of this analysis are
reported in Fig. 3 and show a marked dose-dependent decrease
of mitochondrial uncoupled respiration by NAD-dependent
substrates, but not by succinate. In fact, the uncoupled-
respiration rates by pyruvate/malate, were decreased by 31%
(p<0.05, n=8) and 41% (p<0.01, n=8) in the presence of 10
and 20 μM carvedilol, respectively. These data are consistent
with the above described decrease in the DNP-uncoupled
respiration rates by endogenous substrates (Fig. 2). Similar
inhibitory effects were observed when analyzing the respiratory
fluxes in phosphorylating conditions, i.e. in the presence of
ADP (data not shown). The efficiency of oxidative phosphor-
ylation, measured as coupling of mitochondrial respiration to
ATP production, namely as P/O ratio, showed no change at
any carvedilol concentration, as compared with control cells,
either with pyruvate/malate (P/O=2.53±0.09) or succinate
(P/O=1.38±0.05) as respiratory substrates (data not shown).
3.2. Effect of carvedilol on OXPHOS enzymes and citrate
synthase activities
To evaluate whether the observed decline of the respiratory
fluxes was due to the alteration of specific mitochondrial
electron transfer complexes, the enzymatic activities of complex
I, complex II+ III and complex IV were measured in digitonin-
permeabilized cell lysates. The data are shown in Table 1 and
reveal a highly significant inhibition by carvedilol of the
rotenone-sensitive NADH-CoQ oxidoreductase (complex I)
activity which decreased by 25%, 27% and 48% in the presence
of 5, 10 and 20 μM carvedilol, respectively. By contrast, the
succinate-cytochrome c oxidoreductase (complex II+ III) and
Table 1
Effect of carvedilol on mitochondrial enzyme activities in H9C2 cells
Enzyme activities
(nmol/min/mg protein)
I II+ III IV Citrate
synthase
Carvedilol (μM)
0 16.1±1.54 14.8±1.68 250.4±25.5 78.45±7.91
1 14.6±1.71 15.3±1.55 254.5±28.9 77.69±4.69
5 *12.1±1.51 14.1±0.91 245.7±17.9 70.61±7.70
10 *11.7±1.32 13.5±1.11 244.8±22.9 71.21±9.19
20 **8.4±1.28 13.8±1.15 217.7±15.7 73.72±9.58
Mitochondrial enzyme activities were measured on permeabilized-cell lysates as
described in Materials and methods. Values are mean±SD from six different
experiments and the significance of differences was analyzed by Student's t test
analysis. *p<0.05; **p<0.001 carvedilol-treated cells versus control cells.
Fig. 4. Effect of carvedilol on ROS generation in intact cells. H9C2 cells were
treated with carvedilol at the indicated concentrations for 24 h before
measurements. ROS production rate was measured in intact cells by following
the linear fluorescence increase caused by the ROS-dependent oxidation of
dichlorofluorescin (DCFH) to the fluorescent compound dichlorofluorescein
(DCF) either in basal condition (▪) and in the presence of permeable NAD-
dependent respiratory substrates (▴). The data, normalized to cell number,
represent the means±SD from six independent experiments. For experimental
conditions, see under Materials and methods. *p<0.03, **p<0.01 carvedilol-
treated cells versus control cells.
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unaffected. The mitochondrial enzyme activities expressed as
relative to citrate synthase, a mitochondrial matrix marker
which was unchanged in carvedilol-treated cells, did show the
same pattern of variations so far described.
3.3. Effect of carvedilol on mitochondrial ROS generation,
GSH and PSH content
A substantial increase in the rate of ROS generation
associated with inhibition of complex I activity by carvedilol
has been previously described in isolated mitochondria [24]. In
order to assess whether a similar effect could occur at cellular
level, measurement of steady-state production of oxygen
radicals has been carried out in carvedilol-treated intact cells.
ROS production was measured either in basal condition or in
the presence of exogenous permeable NAD-dependent sub-
strates. The data obtained are reported in Fig. 4 and show a
dose-dependent increase in the ROS production rate, for both
conditions, with the most significant variations being detected at
10 and 20 μM carvedilol.
To evaluate the impact of carvedilol-treatment on the
oxidative state of the H9C2 cells, the cellular contents of total
glutathione (GSH), of oxidized fraction of glutathione (GSSG)
and of protein sulfhydryl groups (PSH) were measured.
Incubation of cells with carvedilol resulted in a slight but
nevertheless highly significant variation of GSH and PSH
content, which were increased up to 16% (p<0.01, n=6) and
22% (p<0.01, n=6) respectively, as compared with control
cells, already at 5 μM carvedilol without any further change at
higher concentrations. Conversely, the GSSG content was not
significantly changed by carvedilol at any of the utilized
concentrations (data not shown).
3.4. Protective effects of carvedilol-pretreatment on
H2O2-induced cell injury
To test the antioxidant properties of carvedilol in our cellular
system, H9C2 cells were pre-treated with 10 μM carvedilol for
24 h and then exposed to H2O2 in order to mimic a strong
oxidative insult [31].
In a preliminary experiment two different concentrations of
H2O2 were tested for their effect on cell morphology. As shownin Fig. 5, no evident differences were observed by phase-
contrast microscopy between control (Fig. 5A) and carvedilol-
treated cells (Fig. 5B) after exposure to 200 μM H2O2 for 2 h
(Figs. 5C and D, respectively). On the other hand, marked cell
shrinkage and membrane blebbing could be observed in H9C2
cells (48%±11% of total cells as counted in five different fields
from three independent experiments) as early as 30 min after
exposure to a higher (500μM)H2O2 concentration in control cells
(Fig. 5E), but not in carvedilol pre-treated cells (Fig. 5F). Based on
these observations (see also Ref. [31]), a range of sublethal doses,
as monitored by trypan blue exclusion test (data not shown), up to
200 μM H2O2, was chosen for further experiments.
Results of the analysis of the effect of H2O2-exposure on
mitochondrial respiratory capacities are shown in Fig. 6.
Incubation of H9C2 cells with H2O2 resulted in a significant
dose-dependent decrease of endogenous DNP-uncoupled
respiration rate in intact cells (Fig. 6A), which was reduced
by 17%, 45% and 59%, at concentrations of 50, 100 and
200 μM H2O2, respectively. Consistently, H2O2-exposure
caused a marked inhibition of maximal respiratory fluxes by
NAD-dependent substrates (decreased by 48% and 59% at 100
and 200 μM H2O2, respectively) (Fig. 6B) and by succinate
(decreased by 36% and 33% at 100 and 200 μM H2O2,
respectively) (Fig. 6C) as measured in digitonin-permeabilized
cells. Pre-treatment of cells with 10 μM carvedilol resulted in a
significant protective effects on H2O2-induced injury of
respiratory chain function, since the respiratory rates were
kept very close to control values even at the highest H2O2
concentrations. It is noteworthy that the addition of soluble
cytochrome c (2 μM) to H2O2-exposed permeabilized cells
leads to a partial recovery of the succinate-dependent respiration
rate without having any effect on the respiratory flux by NAD-
dependent substrates. Interestingly, the above protective effect
on mitochondrial function was not observed when control cells
Fig. 5. Protective effect of carvedilol on morphological changes induced by H2O2 in H9C2 cells. H9C2 cells were pre-treated with 10 μM carvedilol for 24 h and then
exposed to H2O2 as described in Materials and methods and examined by contrast-phase microscopy (magnification ×100). Control cells (A); carvedilol-treated cells
(B); control cells, 2 h after exposure to 200 μM H2O2 (C); carvedilol-pretreated cells, 2 h after exposure to 200 μM H2O2 (D); control cells, 30 min after exposure to
500 μMH2O2 (E); carvedilol-pretreated cells, 30 min after exposure to 500 μMH2O2 (F). Each picture shows a representative field of the corresponding group. Bars:
40 μm. Small arrows, in panel E, indicate extensive cell surface blebbing.
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carvedilol (data not shown). This, although highlighting an
indirect mitochondria-mediated protection by carvedilol, does
not exclude the possibility of a synergic effect due to a direct
antioxidant (chemical) action of residual membrane-embedded
drug molecules in the case of pre-treated cells.
In the light of the mitochondrial complex I-specific
inhibitory action of carvedilol we tried to mimic the protective
effect of the drug on the H2O2-mediated oxidative insult by pre-
treating H9C2 cells with rotenone, a widely used and well-characterized complex I inhibitor. First, we have titrated the
dose-dependent decrease of the cellular respiratory fluxes by
rotenone in order to select a concentration of the drug resulting
in a degree of inhibition comparable to the one observed in
10 μM carvedilol-treated cells. As shown in Fig. 7, the maximal
respiratory fluxes by NAD-dependent substrates in cells
incubated for 24 h with 0.1 nM rotenone were decreased by
30% (n=4; p=0.05) as compared with control cells, while no
significant difference could be detected when using succinate as
respiratory substrate. The 0.1 nM rotenone-pretreated cells also
Fig. 6. Protective effect of carvedilol on H2O2-induced decay of mitochondrial respiration. H9C2 control cells (▪) and carvedilol-pretreated (10 μM carvedilol for
24 h) H9C2 cells (□) were exposed to H2O2 for 2 h as described under Materials and methods. DNP-uncoupled respiration rates were measured polarographically in
intact cells (A) or in digitonin-permeabilized cells in the presence of pyruvate/malate (B) or succinate (C) as respiratory substrates. Grey squares, in panel C, indicate
the effect of cytochrome c addition on uncoupled succinate-dependent respiration rate of digitonin-permeabilized cells. The data represent the means±SD from five
independent experiments. For experimental conditions, see under Materials and methods. *p<0.001, H2O2-exposed cells versus control cells; **p<0.05,
***p<0.001, carvedilol-pretreated H2O2-exposed cells versus H2O2-exposed cells.
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control cells (data not shown). The rotenone-pretreated cells
were protected from the H2O2-induced decay of mitochondrial
respiratory fluxes (Fig. 7).
The effect of carvedilol pretreatment on intracellular total
glutathione (GSH), oxidized fraction of glutathione (GSSG) and
protein sulfhydryl groups (PSH) content in H2O2-exposed cells
was also evaluated and the results are reported in Fig. 8.
Incubation of H9C2 cells with H2O2 resulted in a dramatic dose-
dependent decline of GSH and of PSH content which decreasedFig. 7. Protective effect of partial inhibition of complex I by a sub-saturating
rotenone concentration on H2O2-induced decay of mitochondrial respiration.
H9C2 cells were pre-treated with 0.1 nM rotenone for 24 h and then exposed to
200 μM H2O2 as described in Materials and methods. DNP-uncoupled
respiration rates by pyruvate/malate or succinate were measured polarographi-
cally in control cells (grey bars), cells exposed to H2O2 (filled bars), rotenone-
treated cells (open bars) and rotenone-pretreated cells exposed to H2O2 (hatched
bars) as described under Materials and methods. Mean values from four
independent experiments±SD, are expressed as percentage of control cells.
*p<0.05, rotenone-treated cells versus control cells; **p<0.02, rotenone-
pretreated H2O2-exposed cells versus H2O2-exposed cells.by 37%, 54% and 70% and by 29%, 50% and 67% at 50, 100
and 200 μMH2O2, respectively, as compared with control cells.
In parallel a four-, six- and seven-fold increase of GSSG cellular
content with 50, 100 and 200 μM H2O2, respectively, was
observed. Pretreatment of cells with carvedilol resulted in a
partial but significant recovery of GSH and PSH content and in
a reduction of GSSG amount as compared to H2O2-exposed
cells. In particular, in carvedilol pretreated cells, the cellular
contents of GSH and PSH were both increased by as much as
46% at 200 μMH2O2, as compared with H2O2-exposed cells. A
relative decrease by up to 68% of GSSG content was observed
at the same H2O2 concentration in carvedilol pretreated cells as
compared with untreated H2O2-exposed cells.
We have also measured GSH, GSSG and PSH content in
rotenone-pretreated and in rotenone-pretreated, H2O2-exposed
cardiomyocytes. No significant difference was detected
between control cells and rotenone-pretreated cells before or
after H2O2-exposure, with the exception of a significative
increase (35%, p=0.021) of PSH content in rotenone-
pretreated, H2O2-exposed cells vs. H2O2-exposed control cells.
4. Discussion
In the present work we have characterized, for the first time,
the impact of carvedilol-treatment on the mitochondrial
functions and ROS metabolism of heart-derived H9C2 cells
and its protective effect against H2O2-induced oxidative stress.
It has to be pointed up that, although the effect of carvedilol
treatment on the respiratory chain activity has already been
described in isolated mitochondria [24,25,32], the increasing
evidences of the crucial importance of the functional interac-
tions of these organelles with cytoskeleton, other subcellular
organelles and cytosol motivate the need to evaluate the effect
of the drug under conditions approximating more closely the in
vivo situation. For this reason, we have standardized, for the
first time, the methods for a detailed analysis of mitochondrial
Fig. 8. Effect of carvedilol on total glutathione (GSH), oxidized glutathione (GSSG) and protein sulfhydryl groups (PSH) content in H2O2-induced oxidative stress.
The experimental conditions are the same described in the legend to Fig. 6. Total glutathione (GSH), protein thiol groups (PSH) and oxidized glutathione (GSSG)
contents were measured in total cell lysates of control cells (grey bars) and of cells exposed for 2 h to H2O2 without (filled bars) or after (open bars) 24 h pre-treatment
with 10 μM carvedilol. The data represent the means±SD from five independent experiments. For experimental conditions, see under Materials and methods.
#p<0.05, carvedilol-treated cells versus control cells; *p<0.001, H2O2-exposed cells versus control cells; **p<0.01, carvedilol-pretreated H2O2-exposed cells versus
H2O2-exposed cells.
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digitonin-permeabilized H9C2 cells ( Fig. 1), thus keeping the
organelles in a more physiological environment. The concen-
trations of carvedilol used in our experiments and already
reported by other groups [24,32–35], were chosen considering
that although a carvedilol plasma concentration of 0.3 μmol/L
was reached after one oral dose of 50 mg [36], the concentration
in cellular membranes may be much higher on the basis of its
lipophilic structure [37].
In our experimental conditions we have found a significant
dose-dependent decline of mitochondrial respiratory fluxes by
carvedilol-treatment. The decrease of the respiration rate by
endogenous substrates in intact cells was more pronounced
when measured in the presence of the uncoupler DNP, i.e. under
maximal respiratory fluxes, as compared with basal respiration
rates. The data also indicate a dose-dependent decrease of the
stimulatory effect of the uncoupler DNP on the endogenous
respiration rates. This could be explained by a partial
uncoupling effect of carvedilol, in agreement with previous
results obtained with isolated mitochondria [24,32]. This was
also confirmed by a slight (− 20%) but significant (p<0.03)
decrease of the RCR values by NAD-dependent substrates in
carvedilol-treated cells as compared with control cells. The
maximal oxygen consumption rates (in the presence of DNP) in
digitonin-permeabilized cells, exhibited a significant decrease
only in the presence of NAD-dependent respiratory substrates.
These results would suggest a specific inhibition by carvedilol
on the upstream segment of the mitochondrial respiratory chain.
In fact, by measuring the specific enzymatic capacities of the
mitochondrial respiratory complexes, we have detected a
consistent decline of complex I activity subsequent to
carvedilol-treatment. The previously reported inhibitory effect
of carvedilol on isolated mitochondria as well as on purified
complex I [24], would favour the hypothesis of a direct off-
target action of the drug on the activity of this respiratorycomplex by a still unclear mechanism. On the other hand, the
lack of effect on mitochondrial bioenergetic function in animal
models [38,39] could be ascribed to the treatment procedure and
possibly to the different concentrations reached by the drug in
the cardiac tissue.
The respiratory complex I and complex III are the major sites
for the production of oxygen radical species and their defective
activities could cause a significant increase in ROS production
[21,40]. Indeed, an increase of oxygen radicals production
associated with the carvedilol-inhibition of the steady-state
respiration by NAD-dependent substrates has been previously
shown in isolated mitochondria [24]. The increase of cellular
ROS production observed in carvedilol-treated cells respiring
on endogenous substrates (Fig. 4) could be possibly associated
with the above inhibition of the mitochondrial complex I. This
effect becomes, in fact, more evident in the presence of
saturating concentrations of cell permeant NAD-dependent
substrates (Fig. 4) which leads to a higher electron pressure on
complex I and to an increase in the reduction level of its redox
centers. It is worth noting that the observed increase in ROS
production could be also due to a lowered efficiency of the
scavenging apparatus. However, no variations were found in the
catalase and Cu/Zn superoxide dismutase activities (data not
shown). Actually, an increase of PSH and of total glutathione
(GSH) was detected in carvedilol-treated cells without any
influence on the GSSG relative amount. This finding is in line
and extends previous observation by Oliveira et al. who have
demonstrated, in isolated mitochondria, a specific protective
effect of carvedilol against the oxidation of mitochondrial
membrane PSH resulting in the final inhibition of the MPT pore
opening [23].
Some of the carvedilol effects have been assigned to its
antioxidant properties [6,12] which might contribute to the
cardio-protective action. The antioxidant activity of carvedilol
has been tested by studying the effects of carvedilol (10 μM)
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peroxide, one of the major reactive oxygen intermediates
produced in the failing myocardium [41]. The exposure of
control cells to H2O2 induces a dose-dependent inhibition of the
maximal respiratory capacities by endogenous and exogenous
substrates (either pyruvate+malate or succinate) as measured in
intact and in digitonin-permeabilized cells, respectively (Fig. 6).
Strikingly, pre-treatment of H9C2 cells with carvedilol results in
a marked protection against H2O2-mediated cytotoxicity (Fig.
6). The lack of protection in cells simultaneously exposed to
carvedilol+H2O2 excludes the possibility of an effect solely due
to a direct antioxidant action of the drug.
A digitonin-induced cytochrome c release from mitochon-
dria [42] could be also involved in the lower mitochondrial
respiration rates observed in permeabilized H2O2-exposed cells.
Indeed, the addition of cytochrome c, while having no effect on
control cells and on H2O2-exposed cells respiring on NAD-
dependent substrates, substantially recovered the H2O2-depen-
dent decline of succinate-elicited respiration rate (Fig. 6C). The
absence of a stimulatory effect of exogenous cytochrome c on
pyruvate/malate-dependent respiration could indicate a full
control by complex I on the respiratory flux, under these
conditions of mitochondrial damage, which would override any
effect of a partial cytochrome c depletion. On the other hand,
the possibility that the loss of cytochrome c could specifically
occur in the unphysiological condition of a rotenone-inhibited
respiratory chain utilizing succinate as electron donor, cannot be
excluded [43,44].
Incubation of H9C2 cells with H2O2 results also in a dose-
dependent decline of total glutathione (GSH) and PSH content
with a parallel increase of GSSG cellular content (Fig. 8). Pre-
treatment of cells with carvedilol induces a partial, but
significant maintenance of total glutathione (GSH) and PSH
cellular content and in a decrease of GSSG as compared to
H2O2-exposed cells. This effect could be of the utmost
importance in conditions where the prevention of protein thiol
oxidation by carvedilol would protect from the apoptotic cell
death caused by the calcium-induced mitochondrial perme-
ability transition pore (MPTP) [23,25]. It is also important to
underline that complex I is known to possess critical active thiol
groups which make this complex particularly vulnerable to
oxidative modification [45]. The observed recovery of maximal
respiratory fluxes in carvedilol pretreated H2O2-exposed cells,
respiring on endogenous and exogenous substrates, could be
directly related to the decrease of the oxidized glutathione
fraction (GSSG) (Fig. 8). The ability of carvedilol to preserve
the redox status of critical mitochondrial proteins has also been
proposed to explain its protective effect against doxorubicin-
induced mitochondrial cardiotoxicity [35,38,39]. In this condi-
tion, cardiac mitochondria are implicated as primary targets of
doxorubicin toxicity, which is likely to be mediated by highly
reactive oxygen free radical species generated from mitochon-
drial complex I.
The mild pro-oxidant effects of carvedilol and its beneficial
H2O2-protective activity could appear somehow contradictory.
However, a preconditioning-like mechanism could well con-
ciliate this Janus-faced action of carvedilol.The “ischemic preconditioning” was initially described by
Murray and colleagues in 1986 [46], but the concept has
thereafter been extended also to non-ischemic stress conditions
such as hypoxia, stretch and exposure to reactive oxygen
radicals and chemicals [31,47–49]. This mechanism now
represents a well-established tool for studying oxidant pathways
of protection and injury [50]. Recently, a moderate increase in
ROS promoted by antiapoptotic Bcl-2 family members has been
suggested to be one of the mechanisms to prevent cell death, by
enhancing antioxidant defences and preparing cells to a better
response against acute oxidative stress [51].
Therefore, the carvedilol-dependent inhibition of complex I
and the associated production of sublethal levels of ROS could
produce preconditioning cytoprotection against subsequent
oxidative damage possibly by modulating the antioxidant
response and/or the redox state of specific protein or lipid
messengers. The similar protective effect from H2O2-mediated
oxidative insult observed in H9C2 cells pre-treated with a sub-
saturating concentration of rotenone (Fig. 7), however, is not
associated with any change of GSH, GSSG and PSH content in
rotenone-pretreated cells. This would suggest that the pre-
conditioning effect could occur by a different mechanism
possibly involving enzymatic ROS-scavenging activities not
analyzed in the present paper. The significative increase of PSH
content (+35%, p=0.021) in rotenone-pretreated, H2O2-
exposed cells vs. H2O2-exposed control cells might put in
evidence an important role of protein sulfhydryl groups in the
antioxidant effect.
In conclusion, on the basis of our results, the protection of rat
heart H9C2 cells from H2O2-induced damage can be ascribed to
a double action of carvedilol, i.e. a direct antioxidant effect and
a preconditioning-like mechanism via mitochondrial complex I
inhibition. Induction of key cellular antioxidants by carvedilol
in cardiovascular cells might be an important mechanism
underlying its protective effects observed in various cardiovas-
cular disorders.
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